[go: up one dir, main page]

ES2571409T3 - Antagonistas espiro-cíclicos de TRPV4 - Google Patents

Antagonistas espiro-cíclicos de TRPV4

Info

Publication number
ES2571409T3
ES2571409T3 ES12800913T ES12800913T ES2571409T3 ES 2571409 T3 ES2571409 T3 ES 2571409T3 ES 12800913 T ES12800913 T ES 12800913T ES 12800913 T ES12800913 T ES 12800913T ES 2571409 T3 ES2571409 T3 ES 2571409T3
Authority
ES
Spain
Prior art keywords
phenyl
3alkyl
het
halogen
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12800913T
Other languages
English (en)
Inventor
Carl Brooks
Mui Cheung
Hilary Eidam
Krista Goodman
Marlys Hammond
Mark Hilfiker
Jaclyn Patterson
Patrick Stoy
Guosen Ye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Application granted granted Critical
Publication of ES2571409T3 publication Critical patent/ES2571409T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de fórmula (I):**Fórmula** en donde: R1 es hidrógeno, alquilo C1-3, CH2OH, CH2-O-CH3, CH2OCH2Ph, CH2CN, CN, halógeno, o C(O)OCH3; R2 es independientemente hidrógeno, CN, CF3, halógeno, SO2-alquiloC1-3, alquilo C1-3 o C≡CH; R3 es hidrógeno, alquilo C1-2, CF3 o -OH; R4 es hidrógeno, halógeno, o alquilo C1-3; X es CR4 o N; A es (CH2)n-fenilo, (CH2)n-naftilo, (CH2)n-C(O)-fenilo, (CH2)n-dihidroindenilo, (CH2)n-tetrahidronaftalenilo, (CH2)nbenzodioxol, (CH2)n-dihidrobenzodioxinilo, (CH2)n-dihidroindenilo, (CH2)n-dimetildihidrobenzofuranilo, (CH2)noxotetrahidropirrolilfenilo o (CH2)n-tetrahidrofurilfenilo; en donde el fenilo puede estar sustituido con uno o más sustituyentes seleccionados de: halógeno, NO2, NH2, OH, OCF3, O-alquilo C1-3 , alquilo C1-4, C(CH3)2CO2CH3, C(CH3)2OH, C(CH3)2CN, CH2CN, OCH2CN, OCH2CH2OCH3, OCH2C(O)NHCH3, OCH2C(O)N(CH3)2, C(O)CH3, C(O)O-alquiloC1-3, cicloalquilo C3-6, OCHF2, fenilo, CHF2, CF3, O-fenilo, CN, SO2Me, OCH2-fenilo, CH2O-fenilo, piperidinilo, piperazinilo, oxetano, oxetano-CH3, tetrahidrofurilo, tetrahidropiranilo, morfolinilo, het, O-het, O-CH2-het, o CH2-het; het es piridina, pirimidina, piridazina, pirazina, pirazol, isoxazol, imidazol o triazol; y además, en donde el sustituyente fenilo o het en A puede estar además sustituido con uno o dos: halógeno, O- alquilo C1-3, CN, alquilo C1-4, CF3, C(O)NH2, N(alquilo C1-3)2 o SO2-alquilo C1-3; y el sustituyente alquilo C1-4, cicloalquilo C3-6 o O-alquilo C1-3 en A puede estar además sustituido con CN o OH; o A es (CH2)n-(CRaRb)-(CH2)m-Rx; Ra es hidrógeno o alquilo C1-3, en donde el alquilo C1-3 puede estar además sustituido con uno o más halógenos; Rb es alquilo C1-3; O Ra y Rb junto con el átomo de carbono al que están unidos para formar un grupo cicloalquilo C3-6; O uno de los átomos de carbono en el grupo cicloalquilo C3-6 formado por Ra y Rb se puede sustituir por un oxígeno para formar un grupo oxetano, tetrahidrofurilo o tetrahidropiranilo; Rx es O-fenilo, fenilo, C(O)NH-fenilo o OCH2-fenilo; en donde el fenilo puede estar sustituido con uno o dos sustituyentes seleccionados de: halógeno, O-alquilo C1-3, CN, alquilo C1-4 o CF3; m es 0 o 1; n es 0, 1 o 2; y es 1, 2 o 3; o una de sus sales farmacéuticamente aceptable.
ES12800913T 2011-06-17 2012-06-15 Antagonistas espiro-cíclicos de TRPV4 Active ES2571409T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161498104P 2011-06-17 2011-06-17
PCT/US2012/042607 WO2012174342A1 (en) 2011-06-17 2012-06-15 Trpv4 antagonists

Publications (1)

Publication Number Publication Date
ES2571409T3 true ES2571409T3 (es) 2016-05-25

Family

ID=47357483

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12800913T Active ES2571409T3 (es) 2011-06-17 2012-06-15 Antagonistas espiro-cíclicos de TRPV4

Country Status (5)

Country Link
US (1) US9487507B2 (es)
EP (1) EP2720546B1 (es)
JP (1) JP5969016B2 (es)
ES (1) ES2571409T3 (es)
WO (1) WO2012174342A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2595606T3 (es) 2011-06-17 2017-01-02 Glaxosmithkline Intellectual Property (No. 2) Limited Antagonistas TRPV4
JO3154B1 (ar) 2011-06-17 2017-09-20 Glaxosmithkline Llc عوامل مضادة لـ trpv4
EP2832731A4 (en) 2012-03-27 2015-08-19 Shionogi & Co AROMATIC HETEROCYCLIC CHAIN 5-CORE DERIVED DERIVATIVE HAVING TRPV4 INHIBITORY ACTIVITY
WO2015046193A1 (ja) 2013-09-25 2015-04-02 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体
WO2015136947A1 (en) 2014-03-14 2015-09-17 Raqualia Pharma Inc. Azaspiro derivatives as trpm8 antagonists
RU2018144774A (ru) * 2016-05-19 2020-06-19 Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед Антагонист trpv4
US10968209B2 (en) 2016-05-19 2021-04-06 Glaxosmithkline Intellectual Property (No.2) Limited TRPV4 antagonist
WO2018185701A1 (en) * 2017-04-06 2018-10-11 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists as antitussive agents
CN115427409B (zh) 2020-04-30 2025-02-25 拉夸里亚创药株式会社 作为trpv4拮抗剂的嘧啶-4(3h)-酮衍生物
CN111704613B (zh) * 2020-06-23 2021-07-06 中国人民解放军军事科学院军事医学研究院 咪唑类衍生物及其作为trpv4抑制剂的用途
TW202216143A (zh) 2020-07-16 2022-05-01 日商拉夸里亞創藥股份有限公司 作為眼疾病的治療藥之ｔｒｐｖ４抑制藥
CA3261160A1 (en) 2022-07-08 2024-01-11 Actio Biosciences Inc COMPOUNDS AND THERAPEUTIC METHODS
CN120435476A (zh) * 2023-04-18 2025-08-05 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
WO2024217452A1 (zh) * 2023-04-18 2024-10-24 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE482945T1 (de) * 1998-05-26 2010-10-15 Chugai Pharmaceutical Co Ltd Heterozyklische indolderivate und mono- oder diazaindol-derivate
EP1644358A2 (en) * 2003-07-16 2006-04-12 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
TW200819457A (en) * 2006-08-30 2008-05-01 Actelion Pharmaceuticals Ltd Spiro antibiotic derivatives
EP2118097A1 (en) * 2007-02-01 2009-11-18 Glaxo Group Limited 1-oxa-3-azaspiro[4,5]decan-2-one derivatives for the treatment of eating disorders
WO2008092887A1 (en) * 2007-02-01 2008-08-07 Glaxo Group Limited I-oxa-3-azaspiro (4.5) decan-2-one and 1-oxa-3, 8-diazaspiro (4.5) decan-2-one derivatives for the treatment of eating disorders
GB0707934D0 (en) * 2007-04-24 2007-05-30 Glaxo Group Ltd Chemical compounds
EP2185538A2 (en) * 2007-08-09 2010-05-19 Abbott Laboratories Tetrahydropyridine carboxamide derivatives as trpvl antagonists
TW200944520A (en) * 2008-01-29 2009-11-01 Glaxo Group Ltd Spiro compounds as NPY Y5 receptor antagonists
WO2010011914A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Trpv4 antagonists
JP2012006837A (ja) * 2008-09-30 2012-01-12 Mochida Pharmaceut Co Ltd ２−インドールアクリルアミド類縁体
ES2595606T3 (es) 2011-06-17 2017-01-02 Glaxosmithkline Intellectual Property (No. 2) Limited Antagonistas TRPV4
JO3154B1 (ar) 2011-06-17 2017-09-20 Glaxosmithkline Llc عوامل مضادة لـ trpv4

Also Published As

Publication number Publication date
WO2012174342A1 (en) 2012-12-20
JP2014523420A (ja) 2014-09-11
JP5969016B2 (ja) 2016-08-10
EP2720546B1 (en) 2016-04-06
US9487507B2 (en) 2016-11-08
EP2720546A4 (en) 2014-10-08
US20140113916A1 (en) 2014-04-24
EP2720546A1 (en) 2014-04-23

Similar Documents

Publication Publication Date Title
ES2571409T3 (es) Antagonistas espiro-cíclicos de TRPV4
ES2543567T3 (es) Métodos de utilización de inhibidores de ALK
AR086958A1 (es) Antagonistas de trpv4
ES2662444T3 (es) Derivado de piridina
CO6290648A2 (es) Compuestos de piridina pirimidina t triazina fusionados como inhibidores del ciclo celular
TN2012000614A1 (en) Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
MY169179A (en) Novel piperidine compound or salt thereof
PE20141050A1 (es) Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina
AR092365A1 (es) Derivados de piridopirimidina
NZ587926A (en) Pyridines and pyrazines as inhibitors of pi3k
CO6321244A2 (es) Pirrolopiridinas como inhibidores de cinasa
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
AR079486A1 (es) Compuestos heterociclicos nitrogenados de oxima, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades proliferativas.
AR084001A1 (es) Monobactamas y su uso en el tratamiento de infecciones bacterianas
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
PE20160995A1 (es) Inhibidores de syk
AR092876A1 (es) Inhibidores no nucleosidos de la transcriptasa inversa
PE20091158A1 (es) 5-anilinoimidazopiridinas y metodos de uso
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
ES2630079T3 (es) Moduladores de la ruta del complemento y usos de los mismos
PE20141351A1 (es) Triazolopiridinas
RU2015121431A (ru) Замещенные производные индол-5-ола и их терапевтическое применение
EA201170099A1 (ru) Замещенные пиримидин-4-оновые производные
AR071208A1 (es) Derivados de piridazinona
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen